肝动脉化疗栓塞联合经皮微波凝固疗法治疗中晚期肝癌的临床观察

Clinical observation of the union treatment of hepatic transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatic cellular carcinoma

目的:对比肝动脉灌注化疗栓塞联合经皮微波凝固疗法与单纯肝动脉灌注化疗栓塞治疗中晚期肝癌的疗效差异。方法:将60例肝癌患者随机分为两组,治疗组(34例)予肝动脉灌注化疗栓塞联合经皮微波凝固疗法治疗,对照组(26例)单用肝动脉灌注化疗栓塞治疗,术后随访6～36个月,分析两组之间治疗效果、生存率与术后不良反应发生的差异。结果:治疗组PR 9例,SD 16例,PD 9例,对照组PR 4例,SD 13例,PD9例。治疗组生存12个月以上的有24例(70.59%),对照组仅6例(23.08%),治疗组与对照组1年生存率比较,P<0.01,显示差异有统计学意义。术后不良反应发生方面,两组比较差异无统计学意义。结论:肝动脉灌注化疗栓塞联合经皮微波凝固疗法治疗中晚期肝癌能提高疗效并且提高患者生存率。

Objective： To contrast the curative effect of the union treatment of transcatheter arterial chemoembolization（TACE） and percutaneous microwave coagulation therapy（PMCT） with the simple treatment of TACE in the treatment of hepatic cellular carcinoma（HCC）.Methods： Sixty patients with HCC were randomly divided into two groups.Treatment group included 34 patients,who were treated with TACE＋ PMCT,while control group included 26 patients,who were treated with TACE alone.Sixty patients were followed up 6-36 months to analyze the difference of therapeutic efficacy,survival rate and adverse reaction between two groups.Results： In treatment group（34 patients） PR has 9 cases,SD has 16 cases,PD has 9 cases,while in control group（26 patients） PR has 4 cases,SD has 13 cases,PD has 9 cases.The treatment group survival over 12 months accounted for 24/34（70.59%）,while control group only six were able to survive more than 12 months,accounting for 6/26（23.08%）.It has statistical difference for comparing one year survival rate between treatment group and control group（P0.01）.It has no statistical difference for comparing adverse reaction among the two groups.Conclusion： PMCT combined with TACE can enhance the curative effect on HCC and help increase the patients＇ survival rate,which is a valuable remedy for HCC to prolong long-term survival rate.